V Möbus1, G von Minckwitz2, C Jackisch3, H-J Lück4, A Schneeweiss5, H Tesch6, D Elling7, N Harbeck8, B Conrad9, T Fehm10, J Huober11, V Müller12, I Bauerfeind13, A du Bois14, S Loibl2, V Nekljudova2, M Untch15, C Thomssen16. 1. Department of Gynecology and Obstetrics, Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt. 2. German Breast Group, Neu-Isenburg. 3. Department of Gynecology and Obstetrics, Sana Klinikum Offenbach GmbH, Offenbach. 4. Gynecology and Oncology Practice Hannover, Hannover. 5. National Centre of Tumor Diseases, University of Heidelberg, Heidelberg. 6. Department of Hematology & Oncology at Bethanien-Hospital, Frankfurt. 7. Department of Gynecology and Obstetrics, Sana Klinikum Berlin, Berlin. 8. Department of Gynecology and Obstetrics, University of Munich, Munich. 9. Elisabeth Krankenhaus Kassel, Breast Center, Kassel. 10. Department of Gynecology and Obstetrics, University of Duesseldorf, Duesseldorf. 11. Department of Gynecology and Obstetrics, University of Ulm, Ulm. 12. Department of Gynecology, University Hospital of Hamburg-Eppendorf, Hamburg. 13. Department of Gynecology and Obstetrics, Klinikum Landshut, Landshut. 14. Department of Gynecology & Gynecologic Oncology, Klinikum Essen-Mitte, Essen. 15. Department of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin. 16. Department of Gynecology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
Abstract
BACKGROUND: Dose-dense (dd) regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The German Adjuvant Intergroup Node-positive trial aimed at optimizing intense dd (idd) strategies by evaluating drug combinations and the addition of capecitabine. PATIENTS AND METHODS: Women (aged 18 years and biologically <65 years) with histologically involved axillary lymph nodes were randomly assigned to receive three courses each of epirubicin (E) 150 mg/m2, paclitaxel (P) 225 mg/m2 and cyclophosphamide (C) 2500 mg/m2 (reduced to 2000 mg/m2 after recruitment of 1200 patients) q2w intravenously (i.v.) (iddEPC-regimen) or ddEC (E 112.5 mg/m2 + C 600 mg/m2, i.v. q2w for 4 cycles) followed by paclitaxel weekly (Pw 67.5 mg/m2 i.v. q8d for 10 weeks) plus capecitabine (X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles) (ddEC-PwX-regimen). Further randomization assigned patients to ibandronate for 2 years versus observation and to pegfilgrastim day 2 versus 4. RESULTS: From June 2004 to August 2008, 2994 patients were randomized to either iddEPC (N = 1498), or ddEC-PwX (N = 1496) and started treatment. Median age was 50 years; pN1 (37.8%), pN2 (35.3%); pN3 (26.9%); 46.4% were G3 tumors; 76.9% hormone receptor-positive and 22% HER2-positive. After a median follow-up of 74 months, 645 events and 383 deaths were recorded. Hematological adverse events grades 3-4 were more common with iddEPC (P < 0.001), nonhematological with ddEC-PwX (P = 0.04), even if the toxicity profile of the two regimens was different. At 5 years, estimated disease-free survival rates for ddEC-PwX and iddEPC were 81.7% [95% confidence interval (CI) 79.5-83.6] versus 80.2% (95% CI 78.0-82.2). Hazard ratio (HR)=0.95 (95% CI 0.81-1.11, log-rank P = 0.49). Five-year overall survival rates were 89.4% for ddEC-PwX (95% CI 87.7-91.0) and 89.0% for iddEPC (95% CI 87.2-90.6), HR = 0.85 (95% CI 0.69-1.04, log-rank P = 0.10). CONCLUSION: Adding capecitabine to ddEC-Pw did not improve outcome in comparison to iddEPC but increased toxicity and should not be recommended for further use.
BACKGROUND: Dose-dense (dd) regimens are one of the preferred options for the adjuvant treatment of breast cancer patients with intermediate to high risk. The German Adjuvant Intergroup Node-positive trial aimed at optimizing intense dd (idd) strategies by evaluating drug combinations and the addition of capecitabine. PATIENTS AND METHODS: Women (aged 18 years and biologically <65 years) with histologically involved axillary lymph nodes were randomly assigned to receive three courses each of epirubicin (E) 150 mg/m2, paclitaxel (P) 225 mg/m2 and cyclophosphamide (C) 2500 mg/m2 (reduced to 2000 mg/m2 after recruitment of 1200 patients) q2w intravenously (i.v.) (iddEPC-regimen) or ddEC (E 112.5 mg/m2 + C 600 mg/m2, i.v. q2w for 4 cycles) followed by paclitaxel weekly (Pw 67.5 mg/m2 i.v. q8d for 10 weeks) plus capecitabine (X 2000 mg/m2 p.o. days 1-14, q22 for 4 cycles) (ddEC-PwX-regimen). Further randomization assigned patients to ibandronate for 2 years versus observation and to pegfilgrastim day 2 versus 4. RESULTS: From June 2004 to August 2008, 2994 patients were randomized to either iddEPC (N = 1498), or ddEC-PwX (N = 1496) and started treatment. Median age was 50 years; pN1 (37.8%), pN2 (35.3%); pN3 (26.9%); 46.4% were G3 tumors; 76.9% hormone receptor-positive and 22% HER2-positive. After a median follow-up of 74 months, 645 events and 383 deaths were recorded. Hematological adverse events grades 3-4 were more common with iddEPC (P < 0.001), nonhematological with ddEC-PwX (P = 0.04), even if the toxicity profile of the two regimens was different. At 5 years, estimated disease-free survival rates for ddEC-PwX and iddEPC were 81.7% [95% confidence interval (CI) 79.5-83.6] versus 80.2% (95% CI 78.0-82.2). Hazard ratio (HR)=0.95 (95% CI 0.81-1.11, log-rank P = 0.49). Five-year overall survival rates were 89.4% for ddEC-PwX (95% CI 87.7-91.0) and 89.0% for iddEPC (95% CI 87.2-90.6), HR = 0.85 (95% CI 0.69-1.04, log-rank P = 0.10). CONCLUSION: Adding capecitabine to ddEC-Pw did not improve outcome in comparison to iddEPC but increased toxicity and should not be recommended for further use.
Keywords:
adjuvant chemotherapy breast cancer; capecitabine; dose-dense chemotherapy; high-risk early breast cancer; intense dose-dense chemotherapy; node-positive breast cancer
Authors: Suzette Delaloge; Martine Piccart; Emiel Rutgers; Saskia Litière; Laura J van 't Veer; Franchette van den Berkmortel; Etienne Brain; Aleksandra Dudek-Peric; Miguel Gil-Gil; Patricia Gomez; Florentine S Hilbers; Zaman Khalil; Susan Knox; Sherko Kuemmel; Georg Kunz; Anne Lesur; Jean-Yves Pierga; Peter Ravdin; Isabel T Rubio; Mahasti Saghatchian; Tineke J Smilde; Alastair M Thompson; Giuseppe Viale; Gabriele Zoppoli; Peter Vuylsteke; Konstantinos Tryfonidis; Coralie Poncet; Jan Bogaerts; Fatima Cardoso Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 44.544
Authors: Isabell Witzel; Sibylle Loibl; Ralph Wirtz; Peter A Fasching; Carsten Denkert; Karsten Weber; Hans-Joachim Lück; Jens Huober; Thomas Karn; Marion von Mackelenbergh; Frederik Marmé; Christian Schem; Elmar Stickeler; Michael Untch; Volkmar Müller Journal: Br J Cancer Date: 2019-11-15 Impact factor: 7.640